Profund Advisors LLC lowered its stake in MEDNAX Inc (NYSE:MD) by 10.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,112 shares of the company’s stock after selling 1,308 shares during the period. Profund Advisors LLC’s holdings in MEDNAX were worth $594,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank boosted its position in shares of MEDNAX by 5.9% during the fourth quarter. Amalgamated Bank now owns 18,448 shares of the company’s stock valued at $986,000 after buying an additional 1,035 shares during the period. American International Group Inc. boosted its position in shares of MEDNAX by 0.6% during the third quarter. American International Group Inc. now owns 195,583 shares of the company’s stock valued at $8,434,000 after buying an additional 1,263 shares during the period. Swiss National Bank boosted its position in shares of MEDNAX by 0.4% during the third quarter. Swiss National Bank now owns 343,000 shares of the company’s stock valued at $14,790,000 after buying an additional 1,300 shares during the period. Commerce Bank boosted its position in shares of MEDNAX by 9.6% during the fourth quarter. Commerce Bank now owns 15,868 shares of the company’s stock valued at $848,000 after buying an additional 1,393 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in shares of MEDNAX by 4.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 34,120 shares of the company’s stock valued at $1,823,000 after buying an additional 1,400 shares during the period. Institutional investors own 98.53% of the company’s stock.
MEDNAX stock opened at $57.46 on Monday. The stock has a market capitalization of $5,389.49, a price-to-earnings ratio of 18.30, a PEG ratio of 1.42 and a beta of 0.26. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. MEDNAX Inc has a 12-month low of $40.56 and a 12-month high of $70.72.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now directly owns 39,716 shares of the company’s stock, valued at $2,317,428.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.
A number of brokerages recently issued reports on MD. BMO Capital Markets boosted their price target on MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a report on Monday, February 12th. Piper Jaffray Companies started coverage on shares of MEDNAX in a research note on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 price objective for the company. SunTrust Banks set a $55.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Mizuho reissued a “neutral” rating and issued a $53.00 price objective (up previously from $49.00) on shares of MEDNAX in a research note on Friday, February 9th. Finally, Jefferies Group set a $58.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. MEDNAX currently has an average rating of “Hold” and a consensus target price of $55.58.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.